Purslane-Derived Nanoparticles Ease Colitis in Mouse Models
Published in Biology, Journals, Nanomedicine.
Publication date: October 8, 2026. Research publication: October 7, 2026.
A study in the World Journal of Gastroenterology investigates exosome-like nanoparticles isolated from Portulaca oleracea, commonly known as purslane, as an experimental approach to intestinal inflammation. The work used mouse models of colitis, including dextran sulfate sodium induction and microbiota transplantation.
The researchers report that the particles reduced colitis severity alongside changes in gut microbial communities and metabolites. They also observed lower inflammatory cytokines, improved epithelial tight junctions and reduced endoplasmic reticulum stress, linked to inhibition of the PERK–eIF2α–ATF4 signaling pathway.
The study connects plant-derived nanoparticle research with interactions between gut microbes, metabolism and the intestinal barrier. Its findings remain preclinical: they do not demonstrate effectiveness or safety in people with ulcerative colitis. Eating purslane is also not equivalent to receiving the isolated, characterized particles used experimentally.
Source: Liu and colleagues, World Journal of Gastroenterology, October 7, 2026. DOI: 10.3748/wjg.120885.